Serum IgG2 levels predict long-term protection following pneumococcal vaccination in systemic lupus erythematosus (SLE). Issue 44 (14th October 2020)
- Record Type:
- Journal Article
- Title:
- Serum IgG2 levels predict long-term protection following pneumococcal vaccination in systemic lupus erythematosus (SLE). Issue 44 (14th October 2020)
- Main Title:
- Serum IgG2 levels predict long-term protection following pneumococcal vaccination in systemic lupus erythematosus (SLE)
- Authors:
- Gerard, Anne-Laure
Goulenok, Tiphaine
Bahuaud, Mathilde
Francois, Chrystelle
Aucouturier, Pierre
Moins-Teisserenc, Helene
Batteux, Frédéric
Papo, Thomas
Sacre, Karim - Abstract:
- Highlights: SLE patients are highly susceptible to pneumococcal infection. >50% of SLE patients fail to reach immune protection after pneumococcal vaccination. IgG2 serum level before vaccination is strongly indicative of long-term protection. Abstract: Systemic lupus erythematosus (SLE) patients are at risk for pneumococcal infection. Twenty-one consecutive SLE patients (40[25–75] years) received the sequential PCV13/PPSV23 vaccine and factors associated with long-term protection were analyzed. Immune protection, defined by an antigen-specific IgG concentration ≥1.3 µg/mL for at least 70% of 7 pneumococcal serotypes was assessed at baseline, 2, 6, 12 and 36 months defining long-term protection. Only 10 patients showed pneumococcal immune protection 36 months after vaccination. Eleven (52.4%) patients had no long-term protection with a seroconversion that never or only transiently occurred. SLE disease features, treatment received and immunological characteristics did not differ between protected and unprotected patients except for the pre-vaccination IgG2 serum levels. Serum IgG2 level >2.125 µg/ml showed a sensitivity of 100% and a specificity of 90.9% for long-term protection. Sequential pneumococcal vaccination conferred poor immune protection in SLE. Baseline IgG2 serum level identified patients able to benefit from pneumococcal vaccination.
- Is Part Of:
- Vaccine. Volume 38:Issue 44(2020)
- Journal:
- Vaccine
- Issue:
- Volume 38:Issue 44(2020)
- Issue Display:
- Volume 38, Issue 44 (2020)
- Year:
- 2020
- Volume:
- 38
- Issue:
- 44
- Issue Sort Value:
- 2020-0038-0044-0000
- Page Start:
- 6859
- Page End:
- 6863
- Publication Date:
- 2020-10-14
- Subjects:
- Systemic erythematosus lupus -- Pneumococcal vaccination -- Immune protection -- IgG2
Vaccines -- Periodicals
615.372 - Journal URLs:
- http://www.sciencedirect.com/science/journal/0264410X ↗
http://www.clinicalkey.com/dura/browse/journalIssue/0264410X ↗
http://www.clinicalkey.com.au/dura/browse/journalIssue/0264410X ↗
http://www.elsevier.com/journals ↗ - DOI:
- 10.1016/j.vaccine.2020.08.065 ↗
- Languages:
- English
- ISSNs:
- 0264-410X
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 9138.628000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 14413.xml